Business
Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
~ Achieved First Quarter 2025 Total Net Revenues of $8.8 Million, Up 18% Year Over Year ~ ~ Positive Momentum from Company’s Refined, Targeted Sales Strategy and Enhanced Patient Support Services ~ ~ PEDMARQSI Now Commercially Available in Germany and the United Kingdom ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., May 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today reported
About this update from Fennec Pharmaceuticals Inc.
[{"type":"image","alt":"Fennec Pharmaceuticals Inc.","displaySize":"","headline":null,"caption":"Fennec Pharmaceuticals Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":121,"height":66,"url":"https://media.zenfs.com/en/globenewswire.com/e01604120df1fa3b9ec5192e4215917f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UkeWnOD1xSZWjTITE4vjkA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTExNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e01604120df1fa3b9ec5192e4215917f","width":121,"height":66}},"lazy":false},{"type":"text","content":"~ Achieved First Quarter 2025 Total Net Revenues of $8.8 Million, Up 18% Year Over Year ~","length":94,"tagName":"p"},{"type":"text","content":"~ Positive Momentum from Company’s Refined, Targeted Sales Strategy and Enhanced Patient Support Services ~","length":107,"tagName":"p"},{"type":"text","content":"~ PEDMARQSI Now Commercially Available in Germany and the United Kingdom ~ ","length":74,"tagName":"p"},{"type":"text","content":"~ Management to Host Conference Call Today at 8:30 a.m. ET ~ ","length":70,"tagName":"p"},{"type":"text","content":"RESEARCH TRIANGLE PARK, N.C., May 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today reported its financial results for the first quarter ended March 31, 2025 and provided a business update.","length":263,"tagName":"p"},{"type":"text","content":"“In the first quarter, we sharpened our strategic focus and achieved sustainable growth across key PEDMARK® accounts. Importantly, our Fennec HEARS™ patient support program has been newly revamped to ensure growth with a seamless, supportive experience for both providers and adolescent and young adult, or AYA, cancer patients at every step of the PEDMARK® journey,” said Jeff Hackman, chief executive officer of Fennec Pharmaceuticals. “Looking ahead, we are energized by the momentum that we are building and remain committed to executional excellence. We are deepening our relationships with key accounts and expanding adoption with new and existing customers. With this strong foundation and forward vision, we are confident in our ability to drive value for patients, providers, and shareholders.”","length":803,"tagName":"p"},{"type":"text","content":"Business Highlights:","length":20,"tagName":"p"},{"type":"list","items":[{"val":...